What science can do stories Featured articles Transforming breast cancer care for underserved patient populations Articles Strengthening health systems through the Partnership for Health System Sustainability and Resilience (PHSSR) Articles Keep up to date with the latest news By...
Separately, Britains biggest pharmaceutical group said on Monday that its Imfinzi treatment had been approved in the EU as the first and only immunotherapy for patients with limited-stage small cell lung cancer, whose disease has not progressed after platinum-based chemoradiation therapy.AstraZeneca als...
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer Corporate Press Release 28 February 2025 Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at lea...
AstraZeneca , a science-led , patient focused pharmaceutical company , and AC Health , a healthcare corporation with a portfolio that includes hospitals , clinics and digital health , have partnered to push for early screening for lung cancer utilizing AI through the Lung Ambition Alliance . 1 ...
In the lung cancer field, AstraZeneca boasts several blockbuster products, includingOsimertinib(third-generation EGFR-TKI),Trastuzumab deruxtecan(antibody-drug conjugate, ADC), andDurvalumab(PD-L1 inhibitor). Notably, Osimertinib occupies a significant position in the EGFR inhibitor market, although it ...
According to a July 19, 2021 press release, AstraZeneca’s Imfinzi (durvalumab) has been approved by China’s National Medical Products Administration for the first-line treatment of adult patients in China with extensive-stage small cell lung cancer (ES-SCLC) in combination with stand...
An archive of STAT coverage of AstraZeneca, a British-Swiss biopharma company that offers products for conditions ranging from cancer to Type 2 diabetes.
SINGAPORE -- The International Association for the Study of Lung Cancer 2023 World Congress of Lung Cancer (IASLC 2023 WCLC), held Sept. 9-12 in Singapore, featured many milestone studies in treating lung cancer.AstraZeneca showed a particularly remarkab
AstraZeneca’s Imfinzi Gains EU Approval as First Immunotherapy for Limited-Stage Small Cell Lung Cancer Mar. 17, 2025 at 3:22 a.m. ET on TipRanks.com AstraZeneca Acquires EsoBiotec to Revolutionize Cell Therapy Mar. 17, 2025 at 3:09 a.m. ET on TipRanks.com AstraZeneca PLC ...
Let's see how we can help you! Discover the right solution for your team The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution....